NCT00393978View on ClinicalTrials.gov

Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2014

Conditions
Bipolar DisorderCannabis-Related Disorder
Interventions
DRUG

Quetiapine and placebo

placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).

DRUG

Quetiapine and Topiramate

topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).

Trial Locations (1)

45219-0516

University of Cincinnati Medical Center, Cincinnati

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Cincinnati

OTHER

NCT00393978 - Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania | Biotech Hunter | Biotech Hunter